U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 3C7H5O3.Bi
Molecular Weight 620.3196
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BISMUTH TRISALICYLATE

SMILES

c1ccc(c(c1)C(=O)O)O.c1ccc(c(c1)C(=O)O)[O-].c1ccc(c(c1)C(=O)[O-])[O-].[Bi+3]

InChI

InChIKey=REKWPXFKNZERAA-UHFFFAOYSA-K
InChI=1S/3C7H6O3.Bi/c3*8-6-4-2-1-3-5(6)7(9)10;/h3*1-4,8H,(H,9,10);/q;;;+3/p-3

HIDE SMILES / InChI

Molecular Formula C7H5O3
Molecular Weight 137.1131
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Bi
Molecular Weight 208.9804
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/international/bibrocathol.html | https://clinicaltrials.gov/ct2/show/NCT01357538 | https://www.drugs.com/international/noviform.html | https://www.ncbi.nlm.nih.gov/pubmed/17003947

Bibrocathol (trade names Noviform and Posiformin) is a well-established topical antiseptic for the treatment of acute eyelid diseases like blepharitis. Eye ointments containing 2 or 5 % bibrocathol and the excipients liquid paraffin, white soft paraffin, and lanolin have been marketed since 1967 for the treatment of eye irritation, chronic blepharitis, and uninfected corneal injuries. Reports of clinical experience with bibrocathol for inflammation of the edge of the palpebra exist since the beginning of the 20th century. Until recently, no controlled, randomized clinical studies according to the guidelines for Good Clinical Practice for Trials on Medical Products for Human Use (GCP) as defined by the International Conference on Harmonisation (ICH) have been performed with bibrocathol 2 % ointment, as these were not required for marketing authorization in the 1960s. A first double-blind, prospective, controlled, GCP-compliant clinical study was recently performed to assess the efficacy of bibrocathol 5 % (Noviform®) in acute blepharitis. It demonstrated superior efficacy of bibrocathol 5 % ointment as compared to an ointment vehicle (placebo) after 2 weeks of treatment as assessed by a combined measure of slit-lamp examination results and patients’ subjective complaints.

Originator

Sources: Medizinische Klinik (Muenchen, Germany) (1913), 8, 992.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Noviform

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Successful treatment of blepharitis with bibrocathol (Posiformin® 2 %).
2012 Dec
Patents

Sample Use Guides

A strip of 5 mm eye ointment applied 3 times per day to the eye lid
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:19:32 UTC 2021
Edited
by admin
on Sat Jun 26 04:19:32 UTC 2021
Record UNII
K6CH6HC2O8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BISMUTH TRISALICYLATE
Systematic Name English
BISMUTH SALICYLATE
Systematic Name English
BISMUTH, TRIS(2-(HYDROXY-.KAPPA.O)BENZOATO-.KAPPA.O)-
Systematic Name English
BENZOIC ACID, 2-HYDROXY-, BISMUTH(3+) SALT (3:1)
Common Name English
BISMUTH, TRIS(2-HYDROXYBENZOATO-O1,O2)- BISMUTH, TRIS(SALICYLATO)-
Systematic Name English
Code System Code Type Description
CAS
19034-57-2
Created by admin on Sat Jun 26 04:19:32 UTC 2021 , Edited by admin on Sat Jun 26 04:19:32 UTC 2021
ALTERNATIVE
EVMPD
SUB13093MIG
Created by admin on Sat Jun 26 04:19:32 UTC 2021 , Edited by admin on Sat Jun 26 04:19:32 UTC 2021
PRIMARY
ECHA (EC/EINECS)
231-244-8
Created by admin on Sat Jun 26 04:19:32 UTC 2021 , Edited by admin on Sat Jun 26 04:19:32 UTC 2021
PRIMARY
PUBCHEM
16704976
Created by admin on Sat Jun 26 04:19:32 UTC 2021 , Edited by admin on Sat Jun 26 04:19:32 UTC 2021
PRIMARY
MESH
C496893
Created by admin on Sat Jun 26 04:19:32 UTC 2021 , Edited by admin on Sat Jun 26 04:19:32 UTC 2021
PRIMARY
FDA UNII
K6CH6HC2O8
Created by admin on Sat Jun 26 04:19:32 UTC 2021 , Edited by admin on Sat Jun 26 04:19:32 UTC 2021
PRIMARY
CAS
7460-14-2
Created by admin on Sat Jun 26 04:19:32 UTC 2021 , Edited by admin on Sat Jun 26 04:19:32 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY